[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642092":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":18,"locations":28,"responsibleParty":51,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"National and Kapodistrian University of Athens","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide or Tirzepatide",null,"Adults with obesity initiating treatment with semaglutide or tirzepatide as part of routine clinical care. Participants are followed prospectively for 6 months to evaluate weight loss response and its association with genetic risk score.",[13],"Drug: Semaglutide or Tirzepatide",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":10},"DRUG",[9],[19,24],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Maria P Yavropoulou, MD, MSc, PDH","CONTACT","+306936159517","myavropoulou@med.uoa.gr",{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},"Maria Evangelia Koloutsou, MD","+306986606272","mkoloutsou@med.uoa.gr",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Laiko General Hospital, Athens","RECRUITING","Athens","11527","Greece","GR",{"type":37,"coordinates":38},"Point",[39,40],23.72784,37.98376,{"lat":40,"lon":39},[43,45,46,49],{"name":44,"role":21,"phone":22,"phoneExt":10,"email":23},"Maria Yavropoulou, MD, MSc, PHD",{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},{"name":47,"role":48,"phone":10,"phoneExt":10,"email":10},"Nikolaos Tentolouris, Prof","PRINCIPAL_INVESTIGATOR",{"name":25,"role":50,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"type":48,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":54,"oldNameTitle":10,"oldOrganization":10},"Maria Yavropoulou","Consultant Endocrinologist in the 1st Department of Propaedeutic and Internal Medicine, Medical School of the National and Kapodistrian University of Athens (NKUA) and Deputy in Charge of (C.E.R.E.D) - Disorders of Calcium and Phosphate Metabolism","Laikο General Hospital, Athens","100642092","precision-obesity-medicine-genetic-prediction-of-response-to-glp-1gip-agonists-100642092",false,"NCT07653412","Precision Obesity Medicine: Genetic Prediction of Response to GLP-1\u002FGIP Agonists.","Prediction of Response to GLP-1\u002FGIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.","Diagenix","Inclusion Criteria:\n\nAge ≥18 years BMI ≥40 kg\u002Fm² or ≥37 kg\u002Fm² with comorbidities Initiation of semaglutide or tirzepatide\n\nExclusion Criteria:\n\nPrior bariatric surgery Secondary causes of obesity Active malignancy Chronic pancreatitis Family history of medullary thyroid carcinoma","ALL","18 Years",{"count":66,"type":67},220,"ESTIMATED","6 Months","OBSERVATIONAL","Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may contribute to these differences in treatment outcomes.\n\nThe aim of this prospective cohort study is to investigate whether a Genetic Risk Score (GRS) and selected obesity-related single nucleotide polymorphisms (SNPs) can predict weight loss response to semaglutide or tirzepatide in adults with obesity. Participants initiating treatment with either medication will undergo clinical, biochemical, and genetic assessment at baseline and will be followed for six months. The study will evaluate the association between genetic markers and treatment response and develop predictive models integrating genetic and clinical variables. The findings may contribute to the development of personalized treatment strategies for obesity.",[72,73,74],"Obesity (Disorder)","Anti-obesity Agents","Precision Medicine",[76,77,74,78,79],"Obesity","Genetic Risk Score","GLP-1 Receptor Agonist","GIP\u002FGLP-1 Receptor Agonist","2026-06-12",{"date":82,"type":83},"2026-06-17","ACTUAL",{"date":85,"type":83},"2026-04-22",{"date":87,"type":67},"2027-06-30",{"name":5,"class":6},1]